Blood-based cancer analysis with circulating tumor cell and cancer stem cell isolation platforms — the microfluidic, immunomagnetic, and size-based separation technologies enabling non-invasive tumor characterization, treatment monitoring, and metastasis risk assessment representing the fastest-advancing segment in oncology diagnostics — creates the most clinically promising market...